|Day Low/High||187.03 / 189.59|
|52 Wk Low/High||163.31 / 210.19|
We are encouraged with CVS Health's plans to fix what has hurt the company and we reiterate that the stock is still inexpensive.
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure to Continue Without Changes
Jeff and Zev discuss today's activity in the portfolio (the Amgen trim and the Nvidia initiation) and also answer a few member questions!
This sale is about risk management and decreasing our downside exposure to a decision that is left to the courts.
Stocks close up on Friday amid hopes the U.S. and China are making progress on a trade pact and word that Boeing is speeding up its 737 MAX fixes.
VESALIUS-CV is the Latest Study in Amgen's PROFICIO Clinical Program Investigating the Impact of Repatha on CVD in Multiple Patient Populations
In this day and age, companies must be 'disruptors' or get left in the dust.
If You've had a Heart Attack or Stroke, Your Risk of Having Another Cardiovascular Event is Nearly One in Three(1)
With China reducing its GDP forecast and Europe's central bank growing cautious, markets turned lower this week.
THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.
THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 39 th Annual Healthcare Conference at 9:20 a.
Results From TAUSSIG Study Reinforce Repatha's Safety and Efficacy in Patients With Genetic Risk of High Cholesterol
Jim discusses the FDA approval of J&J's esketamine drug, the importance Disney's direct-to-consumer initiative, why you can't take your cue from a stock, and provides a view of Amgen.
Jim Cramer analyzes what's driving the sellers and looks into this out-of-high-growth-into-value rotation.
Markets end volatile week little changed in spite of failed North Korea summit, and congressional testimony from Powell, Lighthizer and Cohen.
First Preclinical Data to be Presented on AMG 510, a First-in-Class KRASG12C Inhibitor for Solid Tumors
The most recent short interest data has been released for the 02/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Jim discusses Home Depot's earnings and the housing market, Macy's and Kohl's, the oil market, and much more!
We made several trades this week as markets edged higher on optimism over a U.S.-China trade deal.
THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif.
The RMPIA rose 10.5% during the first half of the current quarter.
This biotechnology company got it's start California. Watch 'Behind the Label' TheStreet's new video series to learn more.
We lowered a price target and upgraded another position's rating last week.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.